ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

LAUSANNE, Switzerland, Jan. 30, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on Thursday, February 6, 2025, at 2:00 p.m. ET. ZYNLONTA® is a registered trademark of ADC Therapeutics SA. CONTACTS: Investors Marcy Graham ADC Therapeutics [email protected] +1 650-667-64 ...